key: cord-0293246-1aqgac5p authors: Bagchi, Rammyani; Tinker-Kulberg, Rachel; Supakar, Tinku; Chamberlain, Sydney; Ligaba-Osena, Ayalew; Josephs, Eric A. title: Polyvalent Guide RNAs for CRISPR Antivirals date: 2021-02-25 journal: bioRxiv DOI: 10.1101/2021.02.25.430352 sha: 71e47b11eec60a6762dba9194ae60c586a2edb82 doc_id: 293246 cord_uid: 1aqgac5p CRISPR biotechnologies, where CRISPR effectors recognize and degrade specific nucleic acid targets that are complementary to their guide RNA (gRNA) cofactors, have been primarily used as a tool for precision gene editing1 but possess an emerging potential for novel antiviral diagnostics, prophylactics, and therapeutics.2–5 In gene editing applications, significant efforts are made to limit the natural tolerance of CRISPR effectors for nucleic acids with imperfect complementarity to their gRNAs in order to prevent degradation and mutation at unintended or “off-target” sites; here we exploit those tolerances to engineer gRNAs that are optimized to promote activity at multiple viral target sites, simultaneously, given that multiplexed targeting is a critical tactic for improving viral detection sensitivity,3 expanding recognition of clinical strain variants,6 and suppressing viral mutagenic escape from CRISPR antivirals.7 We demonstrate in vitro and in higher plants that single “polyvalent” gRNAs (pgRNAs) in complex with CRISPR effectors Cas9 or Cas13 can effectively degrade pairs of viral targets with significant sequence divergence (up to 40% nucleotide differences) that are prevalent in viral genomes. We find that CRISPR antivirals using pgRNAs can robustly suppress the propagation of plant RNA viruses, in vivo, better than those with a “monovalent” gRNA counterpart. These results represent a powerful new approach to gRNA design for antiviral applications that can be readily incorporated into current viral detection and therapeutic strategies, and highlight the need for specific approaches and tools that can address the differential requirements of precision gene editing vs. CRISPR antiviral applications in order to mature these promising biotechnologies. (pgRNAs) in complex with CRISPR effectors Cas9 or Cas13 can effectively degrade pairs of viral 21 targets with significant sequence divergence (up to 40% nucleotide differences) that are prevalent in 22 viral genomes. We find that CRISPR antivirals using pgRNAs can robustly suppress the propagation 23 of plant RNA viruses, in vivo, better than those with a "monovalent" gRNA counterpart. These results 24 represent a powerful new approach to gRNA design for antiviral applications that can be readily 25 incorporated into current viral detection and therapeutic strategies, and highlight the need for specific 26 approaches and tools that can address the differential requirements of precision gene editing vs. CRISPR antiviral applications in order to mature these promising biotechnologies. Beyond gene editing, another nascent but less-developed application of CRISPR effectors has 49 been as novel antiviral diagnostics, prophylactics, and therapeutics, based on their ability to recognize 50 and degrade viral genomes. 9 Type II CRISPR effector Cas9 and type V CRISPR effector Cas12, 51 which both recognize and introduce breaks into double-stranded DNA (dsDNA) targets, have been 52 used in vitro 7, 10, 11 and animal models 12 to degrade dsDNA viruses as well as to excise proviruses 53 from cells with latent retroviral infection. 13 Because the vast majority of pathogenic viruses are RNA 54 viruses, type VI CRISPR effectors Cas13a (formerly C2c2), Cas13b, and Cas13d, which are RNA-guided RNA endonucleases, also hold significant promise for CRISPR antiviral biotechnologies. 14-17 56 Recent demonstrations of the ability of Cas13 variants to reduce viral load by either degrading viral 57 single-stranded RNA (ssRNA) genomes or viral mRNA have been performed in plant, 18-20 58 mammalian, 21, 22 and human 4, 14 cells, as well as more recently in animal models. 2 Type V and type VI 59 CRISPR effectors also exhibit nonspecific ssDNAse and ssRNAse activity after recognition of their 60 targets, respectively, and this activity has been harnessed in sensitive strategies to detect viral 61 genetic material in diagnostic devices. 14, 15, 23, 24 While all of these applications have shown significant 62 promise for the future of CRISPR antivirals, further maturation of these biotechnologies is required 63 before they can reach their full potential. As an example of the design workflow, we examined SARS-CoV-2, the coronavirus responsible 117 for the COVID19 respiratory infection, which has a (+) ssRNA genome that is 29,903 nt long ( Figure 118 1C and Figure S4 ), and toward which Cas13 has recently shown therapeutic potential in epithelial 119 cells and animal models in suppressing viral propagation. 2-4 We identified 205 pairs of homologous 120 targets (>70% identity) with pgRNA candidates that pass a preliminary biophysical screen (with 121 regards to GC%, secondary structure, and absence of polynucleotide repeats) for a Cas13 RNP. Of CoV-2 virulence in human epithelial cells, 4 is also significantly more tolerant to mismatches between 163 its spacer and target than Cas9 ( Figure S3 ) and does not require specific flanking sequences next to 164 its targets, so RfxCas13d may represent an optimal effector for antiviral applications in that regard. Table S8 ). We hypothesize that the enhanced antiviral suppression observed when 181 using pgRNAs compared to its "monovalent" counterparts is related to the similar improvements found 182 in CRISPR antiviral treatments with multiple, multiplexed gRNAs, 2, 4 and we will note that pgRNAs can Table 4 were generated by either (1) using plasmids containing targets listed in 233 Table S5 or PCR amplification of targets in plasmids using primers listed in Table S9 . All complete sequences of all RNA viruses with human, mammal, arthropoda, aves, and higher plant 323 hosts found in the NCBI Reference Sequence database were subjected to a brute force direct 324 (nucleotide-by-nucleotide, no gaps) alignment for each of their 23 nt sequence targets to each other, considering only sequence polymorphisms at the same site. We considered only the (+) strand, as 326 even for (-) and dsRNA viruses these sequences would match the vast majority of mRNA sequences. Only targets lacking polynucleotide repeats (4 consecutive rU's, rC's, rG's, or rA's) were considered 328 viable targets. Targets derived from different segments or cDNAs of the same viral strain were CRISPR-Cas guides the future of genetic engineering Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded 366 Cas13a in rodents Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile 368 phone microscopy Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 370 and Influenza CRISPR-Cas12-based detection of SARS-CoV-2 The impact of HIV-1 genetic diversity on CRISPR-Cas9 antiviral activity and 374 viral escape A combinational CRISPR/Cas9 gene-editing approach can halt HIV 376 replication and prevent viral escape Diversity and evolution of class 2 CRISPR-Cas systems Antiviral goes viral: harnessing CRISPR/Cas9 to combat viruses in 380 humans Extinction of all infectious HIV 382 in cell culture by the CRISPR-Cas12a system with only a single crRNA CRISPR-Cas based antiviral strategies against 385 HIV-1 Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal 387 keratitis in mice CRISPR/Cas9-based antiviral strategy: Current status and the potential challenge Programmable inhibition and detection of RNA viruses using Cas13 Field-deployable viral diagnostics using CRISPR-Cas13 Cas13d is a compact RNA-targeting type VI CRISPR effector positively 395 modulated by a WYL-domain-containing accessory protein Nucleic acid detection with CRISPR-Cas13a/C2c2 CRISPR-Cas13d mediates robust RNA virus interference 400 in plants Engineering RNA virus interference via the CRISPR/Cas13 machinery in 402 Arabidopsis C2c2 is a single-component programmable RNA-guided RNA-targeting 404 CRISPR effector CRISPR-Cas13a Cleavage of Dengue Virus NS3 Gene Efficiently Inhibits Viral 406 Porcine reproductive and respiratory syndrome virus (PRRSV) inhibition with 408 engineered Cas13d CRISPR-Cas12-based detection of SARS-CoV-2 Multiplexed and portable nucleic acid detection platform with Cas13 Massively parallel Cas13 screens reveal principles for guide RNA design Prediction of off-target activities for the end-to-end design of CRISPR 416 guide RNAs Optimized sgRNA design to maximize activity and minimize off-target 418 effects of CRISPR-Cas9 Virus Variation Resource-improved response to emergent viral outbreaks Pairwise library screen systematically interrogates Staphylococcus aureus 422 Cas9 specificity in human cells Highly efficient RNA-guided genome editing in 424 human cells via delivery of purified Cas9 ribonucleoproteins